Gilead Turns Back To Virology With $1.4bn MYR Acquisition
MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.
You may also be interested in...
Sales of COVID-19 drug Veklury helped keep sales in the black as the pandemic and generic competition weighed on HIV and HCV products; Gilead raised full-year 2021 guidance.
The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.